Optimizing brief, focused symptom assessment in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): The FHNSI-10.

被引：1
|
作者：
Shaunfield, Sara
Yount, Susan
Boyken, Lara
Stoykova, Boyka
Agulnik, Mark
Samant, Sandeep
Cella, David
机构：
[1] Northwestern Univ, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[3] Daiichi Sankyo UK Ltd, Gerrards Cross, London, England
[4] Univ Tennessee, Memphis, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e18743
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18743
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma
    Hedberg, Matthew L.
    Goh, Gerald
    Chiosea, Simion I.
    Bauman, Julie E.
    Freilino, Maria L.
    Zeng, Yan
    Wang, Lin
    Diergaarde, Brenda B.
    Gooding, William E.
    Lui, Vivian W. Y.
    Herbst, Roy S.
    Lifton, Richard P.
    Grandis, Jennifer R.
    JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (01): : 169 - 180
  • [32] Effect of cetuximab in recurrent and refractory squamous cell carcinoma of the head and neck (SCCHN): a case report
    Clorinda Schettino
    Maria Anna Bareschino
    Katia Monaco
    Michele Orditura
    Ferdinando De Vita
    Fortunato Ciardiello
    Targeted Oncology, 2007, 2 : 253 - 257
  • [33] Effect of cetuximab in recurrent and refractory squamous cell carcinoma of the head and neck (SCCHN): a case report
    Schettino, Clorinda
    Bareschino, Maria Anna
    Monaco, Katia
    Orditura, Michele
    De Vita, Ferdinando
    Ciardiello, Fortunato
    TARGETED ONCOLOGY, 2007, 2 (04) : 253 - 257
  • [34] IMMUNOMODULATION WITH DIETHYLDITHIOCARBAMATE (DDTC) IN PATIENTS WITH RECURRENT SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
    PAREDES, J
    REUBEN, J
    HERSH, EM
    ROBBINS, T
    MCCARTHY, K
    HONG, WK
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 405 - 405
  • [35] A phase II study of lapatinib (GW572016) in recurrent/metastatic (RIM) squamous cell carcinoma of the head and neck (SCCHN).
    Abidoye, O. O.
    Cohen, E. E.
    Wong, S. J.
    Kozloff, M. F.
    Nattam, S. R.
    Stenson, K. M.
    Blair, E. A.
    Day, S.
    Dancey, J. E.
    Vokes, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 297S - 297S
  • [36] Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN).
    Wirth, LJ
    Haddad, RI
    Wieczorek, TJ
    Faucher, JL
    Clark, JR
    Norris, CM
    Posner, MR
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 498S - 498S
  • [37] M-VAC chemotherapy and GM-CSF in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)
    Degardin, M
    Cappelaere, P
    Caty, A
    Lefebvre, JL
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 438 - 438
  • [38] Prognostic value of body composition and nutritional assessment in recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCHN) treated with immunotherapy (IO)
    Vidales Sepulveda, Z.
    Choulli, M.
    Fabrego, S.
    Pallares, N.
    Santos, N.
    Llop Serna, S.
    Brenes Castro, J.
    Plana Serrahima, M.
    Juarez Lozano, C. M.
    Brunet, A.
    Melero, M.
    Bermejo, O.
    Vilajosana, E.
    Godino, C.
    Oliva, M.
    Arribas, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S585 - S586
  • [39] The humanistic burden reported by patients diagnosed with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) in Europe
    Singh, P.
    Bennett, B.
    Bailey, T.
    Taylor-Stokes, G.
    Hennessy, L.
    Rajkovic, I.
    Contente, M. C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [40] Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN)
    Zenda, Sadamoto
    Onozawa, Yusuke
    Boku, Narikazu
    Fida, Yoshiyuki
    Ebihara, Mitsuru
    Onitsuka, Tetsuro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (07) : 477 - 481
12345